<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23094" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperammonemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Rimsha</given-names>
          </name>
          <aff>Rawalpindi Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rimsha Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23094.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperammonemia is a metabolic condition characterized by raised levels of ammonia, a nitrogen-containing compound. Ammonia is a potent neurotoxin. Hyperammonemia most commonly presents with neurological signs and symptoms that may be acute or chronic, depending on the underlying abnormality. Hyperammonemia should be recognized early and treated immediately to prevent the development of life-threatening complications such as cerebral edema and brain herniation. This activity reviews the evaluation and management of hyperammonemia and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of hyperammonemia.</p></list-item><list-item><p>Describe the presentation of a patient with hyperammonemia.</p></list-item><list-item><p>Outline the management options available for hyperammonemia.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients with hyperammonemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23094&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23094">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23094.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperammonemia is a metabolic condition characterized by the raised levels of ammonia, a nitrogen-containing compound. Normal levels of ammonia in the body vary according to age. Hyperammonemia&#x000a0;can result from&#x000a0;various congenital and acquired conditions in which it may be the principal toxin. Hyperammonemia may also occur as a part of other disorders that involve various other metabolic abnormalities. Normally, ammonia is produced in the colon and small intestine from where it is transported to the liver to be converted to urea via the urea cycle. Urea, a water-soluble compound, can then be excreted via the kidneys. Ammonia levels rise if the liver is unable to metabolize this toxic compound&#x000a0;as a result of&#x000a0;an enzymatic defect or hepatocellular damage. The levels may also rise if portal blood is diverted to the systemic circulation, bypassing the liver, or there is increased production of ammonia due to an infection with certain microorganisms.<xref ref-type="bibr" rid="article-23094.r1">[1]</xref><xref ref-type="bibr" rid="article-23094.r2">[2]</xref>&#x000a0;Hyperammonemia in adults is most commonly related to cirrhotic liver disease in 90% of the cases. This metabolic abnormality, however, can be seen in numerous other disorders that need to be understood. Ammonia is a potent neurotoxin, and elevated levels in the blood can cause neurological signs and symptoms that may be acute or chronic, depending on the underlying abnormality. Hyperammonemia should be recognized early and treated immediately to prevent the development of life-threatening complications such as cerebral edema and brain herniation. Treatment strategies vary according to etiology.</p>
      </sec>
      <sec id="article-23094.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of hyperammonemia is vast. It is a part of numerous disorders that can be classified as congenital or acquired. The acquired disorders can further be classified as hyperammonemia due to hepatic&#x000a0;causes and non-hepatic causes (causes other than a liver disease). Congenital disorders involving enzymatic defects include urea cycle defects, organic acidemias, congenital lactic acidosis, fatty acid oxidation defect, and dibasic amino acid deficiencies. Other disorders include transient hyperammonemia of the newborn, neonatal Herpes simplex virus (HSV) infection, and severe perinatal asphyxia.</p>
        <p>
<bold>Urea Cycle Enzyme Defects</bold>
</p>
        <p>The urea cycle is an energy-dependent process responsible for the conversion of toxic ammonia into urea, which can then be excreted. Five major steps are involved, each requiring a different enzyme. These include N-acetyl-glutamate synthase, carbamoyl phosphate synthetase (CPS), ornithine transcarbamylase, argininosuccinate synthetase (AS), argininosuccinic acid lyase (AL), and arginase.<xref ref-type="bibr" rid="article-23094.r3">[3]</xref> A defect in any of these enzymes results in impaired function of the urea cycle, leading to the accumulation of ammonia. All of the defects are autosomal recessive, except for ornithine transcarbamylase deficiency, which is X-linked recessive. This is also the most common type of urea cycle disorder, and its prevalence is estimated to be 1:140000.<xref ref-type="bibr" rid="article-23094.r4">[4]</xref> Females who are heterozygous for this defect, and males with some residual function of the enzyme can present later in life. Argininosuccinic acid lyase deficiency is the second most common defect and sometimes is linked to trichorrhexis nodosa. Defects in carbamoyl phosphate synthetase (CPS) and argininosuccinate synthetase (ASS) result in hyperammonemia that presents in the first 24 to 48 hours of life. Hyperammonemia is mild in arginase deficiency, and the associated neuronal damage is due to elevated levels of arginine.</p>
        <p>Other enzymatic defects causing hyperammonemia are associated with additional metabolic abnormalities. Ketosis and acidosis are associated with organic acidemias such as isovaleric acidemia. Elevated pyruvate and lactate levels in congenital lactic acidosis and severe hypoglycemia in acyl CoA dehydrogenase deficiency are seen along with hyperammonemia.</p>
        <p>Transient hyperammonemia of infancy is possibly due to the slow maturation of the urea cycle function seen in premature infants. It usually presents with signs and symptoms of hypoxic-ischemic encephalopathy and intracranial hypertension within the first 24 to 48 hours of life. Severe perinatal asphyxia or neonatal HSV infection may also result in elevated ammonia levels.</p>
        <p>An acquired disease-causing hyperammonemia in children is Reye syndrome, a childhood disorder that occurs most commonly after influenza or varicella infection and ingestion of aspirin. Hyperammonemia is coupled with elevated liver enzymes and lactic acidosis. Hepatomegaly is usually seen on examination. <bold>Liver Disease</bold></p>
        <p>Hepatic encephalopathy is a syndrome of neuropsychiatric manifestations in patients with liver disease, and one of the mechanisms of its development is hypothesized to be hyperammonemia. 10% of the patients with hepatic encephalopathy, however, do not have raised levels of ammonia. Hepatic encephalopathy can be categorized into three main types depending on the underlying cause. They are:</p>
        <list list-type="order">
          <list-item>
            <p>Type A hepatic encephalopathy: acute liver failure due to viral hepatitis, ischemic hepatitis, and ingestion of hepatotoxins. This usually presents with features of acute hepatic encephalopathy along with hepatic synthetic dysfunction.</p>
          </list-item>
          <list-item>
            <p>Type B encephalopathy: portosystemic shunts in patients with no underlying cirrhosis or liver disease. It may be congenital (a rare disorder) or artificially created (for portal vein thrombosis) and can result in hyperammonemia as the blood bypasses the liver.<xref ref-type="bibr" rid="article-23094.r5">[5]</xref>&#x000a0;These conditions can also give rise to features of encephalopathy.</p>
          </list-item>
          <list-item>
            <p>Type C hepatic encephalopathy: cirrhosis and portal hypertension due to chronic Hepatitis B or C virus, biliary atresia, alpha 1 antitrypsin deficiency, Wilson disease, and cystic fibrosis.</p>
          </list-item>
        </list>
        <p>Encephalopathy can be acutely precipitated by renal failure, gastrointestinal bleed, or infection.</p>
        <p>Causes of noncirrhotic hyperammonemia in adults include:</p>
        <list list-type="order">
          <list-item>
            <p>Hematological disorders: multiple myeloma (plasma cells have increased amino acid metabolism) and acute leukemia.</p>
          </list-item>
          <list-item>
            <p>Infections: infections with urease-producing organisms such as <italic toggle="yes">Proteus mirabilis, Escherichia coli, </italic>and<italic toggle="yes"> Klebsiella</italic> may result in severe hyperammonemia in children with congenital defects of the urinary tract&#x000a0;and the elderly with urinary tract infections leading to urinary retention.<xref ref-type="bibr" rid="article-23094.r6">[6]</xref> These bacteria utilize the enzyme urease to hydrolyze urea to ammonium ions (NH), thus causing an elevation in the urinary pH. Ammonium ions change into lipophilic ammonia (NH) in the alkaline urine, and this compound is easily transferred to the venous plexus around the bladder. This can lead to hyperammonemia that may be severe enough to lead to encephalopathy or coma.<xref ref-type="bibr" rid="article-23094.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Unmasked urea cycle defects: As mentioned previously, females who are heterozygous for ornithine transcarbamylase deficiency and males with some residual function of the enzyme can present later in life. They can develop clinical features of hyperammonemia in stressful situations such as increased muscle catabolism due to seizures and starvation, increased protein load delivered in total parenteral nutrition,&#x000a0;gastrointestinal bleeding,&#x000a0;and infections.<xref ref-type="bibr" rid="article-23094.r7">[7]</xref><xref ref-type="bibr" rid="article-23094.r8">[8]</xref><xref ref-type="bibr" rid="article-23094.r7">[7]</xref> Late presentations are fairly common in this defect.</p>
          </list-item>
          <list-item>
            <p>Drugs: Several drugs may give rise to hyperammonemia. Valproic acid&#x000a0;is thought to cause hyperammonemia by inhibiting glutamate uptake by astrocytes.<xref ref-type="bibr" rid="article-23094.r9">[9]</xref> This effect is more likely to be seen in patients with masked urea cycle defects. Some cases of topiramate/valproate-induced hyperammonemic encephalopathy have been reported.<xref ref-type="bibr" rid="article-23094.r10">[10]</xref> Other drugs associated include carbamazepine, salicylates, and sulfadiazine.</p>
          </list-item>
        </list>
        <p>Liver disease is not present in some patients with portosystemic shunts, as described above. The term &#x02018;Type B hepatic encephalopathy,&#x02019; however, is used to describe the neuropsychiatric features seen in the patients with this abnormality.&#x000a0;</p>
      </sec>
      <sec id="article-23094.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hyperammonemia occurs as a result of multiple disorders, hence accurate data on its incidence is difficult to obtain. A gross estimate on the incidence of urea cycle disorders is 1 in 250,000 live births in the United States&#x000a0;and 1 in 440,000 live births internationally.<xref ref-type="bibr" rid="article-23094.r11">[11]</xref></p>
      </sec>
      <sec id="article-23094.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>&#x000a0;Ammonia is produced in various organs of the body by different mechanisms:</p>
        <list list-type="order">
          <list-item>
            <p><bold>Colon:</bold> Bacterial metabolism of protein and urea</p>
          </list-item>
          <list-item>
            <p><bold>Small intestine:</bold> Glutamate degradation by bacteria</p>
          </list-item>
          <list-item>
            <p><bold>Skeletal muscle:</bold> Amino acid transamination and the purine-nucleotide cycle</p>
          </list-item>
        </list>
        <p>Abnormalities in the urea cycle or liver disorders may lead to increased levels of ammonia, which is then transported to the brain, skeletal muscle, and kidneys for elimination.</p>
        <p>
<bold>Role of Ammonia in Neurotoxicity</bold>
</p>
        <p>The exact mechanism by which ammonia results in CNS damage has not been established. It has been hypothesized that various alterations in the neurotransmitter system are responsible for the neuronal damage seen in both acute and chronic hyperammonemia. Animal studies have shown that acute ammonia intoxication in vitro results in elevated extracellular levels of glutamate in the brain. This results in activation of the N-methyl-D-aspartate (NMDA) receptors, which causes decreased phosphorylation of protein kinase C that results in the activation of Na/K-ATPase. The resultant ATP depletion is responsible for ammonia toxicity and is the most probable cause of seizures in acute hyperammonemia.<xref ref-type="bibr" rid="article-23094.r12">[12]</xref></p>
        <p>Another consequence of acute hyperammonemia is cerebral edema. This occurs primarily due to the swelling of astrocytes, which are the only cells involved in ammonia detoxification in the brain. Proposed mechanisms for astrocyte swelling include altered water and K+ metabolism in the astrocytes, activation of tumor suppressor protein p53, increased uptake of certain compounds including pyruvate, lactate, and glutamine and decreased uptake of ketone bodies, glutamate, and free glucose. Cerebral edema leads to raised intracranial pressure, which may result in brain herniation.<xref ref-type="bibr" rid="article-23094.r13">[13]</xref></p>
        <p>Chronic hyperammonemia results in two major pathological changes, both of which result in increased inhibitory neurotransmission.</p>
        <list list-type="order">
          <list-item>
            <p>Increased extra-synaptic glutamate accumulation leading to the downregulation of glutamate receptors. Changes in the glutamate-nitric oxide-cGMP pathway resulting in impaired signal transmission in the N-methyl-D-aspartate (NMDA) receptors. This contributes to the cognitive dysfunction seen in hepatic encephalopathy.<xref ref-type="bibr" rid="article-23094.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Benzodiazepine receptor overstimulation from endogenous benzodiazepines and neurosteroids, resulting in an increased GABAergic tone</p>
          </list-item>
        </list>
        <p>Ammonia increases the transport of tryptophan, an aromatic amino acid, across the blood-brain barrier. The resultant increased serotonin levels in the brain are responsible for anorexia commonly seen in chronic hyperammonemia.</p>
      </sec>
      <sec id="article-23094.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>Hyperammonemia mainly presents with neurological signs and symptoms due to its neurotoxic effects. Early-onset hyperammonemia is seen in neonates at 24-72 hours of life. The neonate becomes symptomatic as ammonia levels rise above 100-150 micromol/L. The family usually gives a history of non-specific symptoms, including lethargy, irritability, and vomiting. As the levels rise, the child may develop hyperventilation and grunting as the ammonium ion stimulates the medullary center of the brain responsible for controlling respiration.</p>
        <p>Late-onset hyperammonemia presents later in life and occurs as a result of multiple congenital and acquired disorders, as described above. Symptoms include irritability, headache, vomiting, ataxia, and gait abnormalities in the milder cases. Seizures, encephalopathy, coma, and even death can occur in cases with ammonia levels greater than 200 micromol/L.<xref ref-type="bibr" rid="article-23094.r14">[14]</xref> Patients with partial defects in urea cycle enzymes develop symptoms only during stressful periods e.g., starvation, pregnancy, surgery, etc. Symptoms may also&#x000a0;be precipitated&#x000a0;due to an increase in protein intake, constipation, aggressive diuresis, use of opioids, or infections like spontaneous bacterial peritonitis.</p>
        <p>Patients may develop intellectual disability, behavioral and psychiatric symptoms in chronic hyperammonemia. This has been linked to glutamine levels in the brain.<xref ref-type="bibr" rid="article-23094.r15">[15]</xref></p>
        <p>
<bold>Physical Exam</bold>
</p>
        <p>Physical exam findings are usually non-specific, including increased respiratory rate and dehydration due to vomiting. Neurological examination may reveal impaired concentration and coordination, slurred speech, disorientation, and hand tremors. Examination findings specific to the underlying disorder may also be seen. An odor of &#x02018;sweaty feet&#x02019; may be present in isovaleric acidemia, and fragile hair may be observed in argininosuccinic acid lyase deficiency.</p>
        <p>Five grades of hepatic encephalopathy have been used to describe both acute and chronic clinical manifestations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Grade 0: subclinical or minimal hepatic encephalopathy categorized by minimal changes in concentration, memory, and intellectual function</p>
          </list-item>
          <list-item>
            <p>Grade 1: changes in sleep pattern, lack of awareness, and shortened attention span</p>
          </list-item>
          <list-item>
            <p>Grade 2: lethargy, apathy, changes in personality, asterixis, and slurred speech</p>
          </list-item>
          <list-item>
            <p>Grade 3: Somnolent but can be aroused, marked confusion, and disorientation of time and space</p>
          </list-item>
          <list-item>
            <p>Grade 4: Coma. The patient may or may not respond to painful stimuli.</p>
          </list-item>
        </list>
        <p>In patients with hepatic encephalopathy due to cirrhosis, several physical examination findings due to hepatic dysfunction and portal hypertension, including jaundice, abdominal distension with shifting dullness, hepatomegaly, pedal edema, spider nevi, gynecomastia, and caput-medusae can also be appreciated.</p>
      </sec>
      <sec id="article-23094.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Normal levels of ammonia vary according to age, being higher in newborns compared to older children or adults. In newborns, gestational and postnatal ages also affect the levels of ammonia.</p>
        <p><bold>Healthy term infants:</bold> 45&#x000b1;9 micromol/L; 80 to 90 micromol/L is considered to be the upper limit of normal.</p>
        <p><bold>Preterm infants:</bold> 71&#x000b1;26 micromol/L, decreasing to term levels in approximately seven days</p>
        <p><bold>Children older than 1 month:</bold> less than 50 micromol/L</p>
        <p><bold>Adults:</bold> less than 30 micromol/L</p>
        <p>In the neonatal period, hyperammonemia presents with non-specific signs and symptoms, and thus important tests to rule out sepsis, meningitis, intracranial hemorrhage, and GI bleed should be considered. Raised levels of ammonia should prompt specific investigations including arterial blood gases, blood glucose, lactate and citrulline levels, plasma and urinary amino acids, urinary ketones, etc. Some additional tests that can be done for diagnosing urea cycle defects include specific enzyme assays on liver biopsy specimens or red blood cells and DNA mutation.</p>
        <p>In patients with hepatic encephalopathy, liver function tests, including levels of liver enzymes and bilirubin and prothrombin time, are helpful to gauge the synthetic function of the liver. Specific tests to diagnose the underlying etiology of non-cirrhotic hyperammonemia should be considered if reasonable clinical suspicion is present.</p>
        <p>Neuroimaging with CT scan or MRI can be helpful for diagnosis, although it will only show the effects ammonia has on the brain. In hyperammonemic encephalopathy, MRI shows diffusion restriction in the insular cortex and cingulate gyrus.<xref ref-type="bibr" rid="article-23094.r16">[16]</xref> These changes may be reversible but may also lead to atrophy. In patients with chronic liver disease, cerebral atrophy with symmetric hyperintensities of the globus pallidus is seen. Asymmetric involvement of the thalami, parietal, occipital, temporal, and frontal cortices can also be seen.<xref ref-type="bibr" rid="article-23094.r17">[17]</xref> The affected areas of the brain in neonates with congenital defects leading to hyperammonemia include the insular sulci and the lentiform nuclei. One reason for the different patterns of involvement in neonates could be that these areas are more metabolically active.<xref ref-type="bibr" rid="article-23094.r18">[18]</xref> Some studies have shown that an increased severity or duration of hyperammonemic insult leads to a greater extent of abnormalities that can be witnessed on neuroimaging.<xref ref-type="bibr" rid="article-23094.r18">[18]</xref></p>
      </sec>
      <sec id="article-23094.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of acute hyperammonemia focuses on decreasing the level of ammonia and controlling specific complications, including cerebral edema and intracranial hypertension. Inborn errors of metabolism may lead to neonatal-onset hyperammonemia or may present as intercurrent episodes of hyperammonemia. These require continual treatments targeted at the specific etiology. The treatment of hepatic encephalopathy differs from that of inborn errors of metabolism.</p>
        <p>
<bold>Treatment to Lower Ammonia</bold>
</p>
        <p>Neonates with inborn errors of metabolism may present with hyperammonemic coma, a serious condition requiring immediate intervention. All protein intake should be stopped, and calories should be provided using glucose solutions. Hemodialysis is preferred over peritoneal dialysis for the rapid removal of ammonia.<xref ref-type="bibr" rid="article-23094.r19">[19]</xref><xref ref-type="bibr" rid="article-23094.r20">[20]</xref>&#x000a0;Continuous arteriovenous or venovenous hemofiltration can also be considered.<xref ref-type="bibr" rid="article-23094.r21">[21]</xref> As the levels of ammonia fall, compounds that convert nitrogenous waste into products other than urea are used. These include sodium benzoate and phenylacetate in the intravenous forms.<xref ref-type="bibr" rid="article-23094.r20">[20]</xref>&#x000a0;Intravenous arginine should also be provided.</p>
        <p>Patients with masked urea cycle defects develop hyperammonemia in conditions of increased stress and should be treated when levels rise greater than 3 times the upper limit of normal. Calories should be provided intravenously by glucose solutions, and all nitrogen intake should be stopped. Intravenous sodium benzoate and phenylacetate should be started. Dialysis should be considered only when ammonia levels do not fall after 8 hours of continual treatment.</p>
        <p>Medical treatment for hepatic encephalopathy is targeted towards decreasing the production of ammonia in the gut. The established first-line therapy for encephalopathy is oral non-absorbable disaccharides, including lactulose and lactitol. These sugars work by decreasing the production and absorption of ammonia in the intestine.<xref ref-type="bibr" rid="article-23094.r22">[22]</xref> They, however, do not affect mortality. The non-absorbable antibiotic, rifaximin, is also used as first-line therapy and is usually given along with the non-absorbable disaccharides.<xref ref-type="bibr" rid="article-23094.r23">[23]</xref>&#x000a0;</p>
        <p>
<bold>Management of Complications</bold>
</p>
        <p>Hypertonic saline is preferred over mannitol for the management of increased intracranial pressure due to cerebral edema.<xref ref-type="bibr" rid="article-23094.r24">[24]</xref><xref ref-type="bibr" rid="article-23094.r25">[25]</xref>&#x000a0;Sedation with propofol and the use of hyperosmolar agents are considered effective for the management of hyperammonemia due to fulminant hepatic failure resulting in cerebral edema and raised intracranial pressure.<xref ref-type="bibr" rid="article-23094.r26">[26]</xref> Corticosteroids induce a negative nitrogen balance and thus should be avoided in the treatment of raised intracranial pressure in neonatal-onset hyperammonemia. Valproic acid should not be used to treat seizures seen in hyperammonemia.<xref ref-type="bibr" rid="article-23094.r9">[9]</xref></p>
        <p>
<bold>Dietary Management</bold>
</p>
        <p>It is logical to assume protein intake needs to be restricted in patients with hyperammonemia. Protein restriction is not recommended, specifically in patients with chronic liver disease as they are already malnourished, and the general consensus is to continue a normal intake of proteins. Some compounds may play a role in lowering ammonia and can be supplemented in the diet. L-carnitine can be used to decrease the frequency of attacks in patients with urea cycle defects.<xref ref-type="bibr" rid="article-23094.r9">[9]</xref> L-ornithine-L-aspartate&#x000a0;may be of use in hepatic encephalopathy as it increases ammonia metabolism in the muscle.<xref ref-type="bibr" rid="article-23094.r27">[27]</xref> Arginine should be supplemented in the diet of patients with urea cycle defects as it becomes an essential amino acid.</p>
      </sec>
      <sec id="article-23094.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Hyperammonemia is itself a condition that may result from a multitude of disorders, as described above. Laboratory and radiological investigations should be done to rule out CNS diseases with clinical findings resembling those seen in hyperammonemia. Examples include meningitis and sepsis in neonates and meningitis, encephalitis, brain tumors, and pseudotumor cerebri in adults. &#x000a0;</p>
        <p>Multiple disorders can present with hyperammonemia like picture but with ammonia levels within a normal range. Disorders of carbohydrate metabolism present with hypoglycemia and hyperuricemia. Ataxia, with genetic and biochemical defects, is caused by various hereditary defects affecting the CNS at multiple levels. Developmental delay and neuronal regression are frequently seen. Methylmalonic acidemia, an inherited disorder of amino acid metabolism with encephalopathy and stroke as a common presentation. Stroke is not seen in patients of hyperammonemia. Homocystinuria is a disorder of methionine metabolism that presents with features of stroke, ectopia lentis, and marfanoid habitus. Posterior reversible encephalopathy syndrome, diffuse hypoxic-ischemic encephalopathy, and seizure disorders may present with neuroimaging findings similar to that of hyperammonemia but occur due to other causes and usually do not have raised levels of ammonia.<xref ref-type="bibr" rid="article-23094.r17">[17]</xref></p>
      </sec>
      <sec id="article-23094.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis depends on the underlying condition responsible for raised ammonia levels. For urea cycle defects, the 11-year-survival rate was reported to be 35% and 87% for patients with early-onset and late-onset hyperammonemia, respectively, in a study in the United States.<xref ref-type="bibr" rid="article-23094.r11">[11]</xref> In patients of severe hepatic encephalopathy, survival probability at 1 and 3 years of follow-up has been reported to be 42% and 23%, respectively.<xref ref-type="bibr" rid="article-23094.r28">[28]</xref></p>
      </sec>
      <sec id="article-23094.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Elevated levels of ammonia, a potent neurotoxin, can result in life-threatening complications due to CNS damage, which includes cerebral edema, raised intracranial pressure, brain herniation, and coma. Osmotic demyelination syndrome is a potential complication of the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency.<xref ref-type="bibr" rid="article-23094.r29">[29]</xref></p>
      </sec>
      <sec id="article-23094.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated regarding the signs and symptoms of hyperammonemia, which include lethargy, confusion, gait abnormalities, and vomiting. Education regarding medication compliance is vital. This is especially important for patients of cirrhosis.&#x000a0;Diet plans should be provided individually to patients, and emphasis should be placed on important dietary restrictions at each visit. Information regarding specific dietary supplements should be provided. Patients should be informed that exercise is not completely restricted, and caloric intake should be increased to avoid protein breakdown in patients who wish to follow an active lifestyle. In children with urea cycle defects, growth and development should be monitored on each visit, and parents should be guided accordingly. Families with an infant diagnosed with urea cycle disorder should be informed of the availability of antenatal tests for diagnosis.</p>
      </sec>
      <sec id="article-23094.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hyperammonemia is a metabolic abnormality that can occur in multiple disorders and can result in serious complications that need to be recognized and treated early. More than 90% of the patients develop hyperammonemia as a result of liver dysfunction, but various other diseases, that can lead to life-threatening complications fairly early in the disease course, need to be kept in mind. Health-care providers need to be well aware of the causes, pathophysiology, clinical signs and symptoms, and treatment strategies for managing hyperammonemia and the underlying defect contributing to the condition. An approach with effective interprofessional communication is required to ensure patient care. The interprofessional team includes internists, gastroenterologists, pediatricians, neonatologists, neurologists, general surgeons, urologists, hematologists, nurses, and pharmacists. Consultations with nephrologists for hemodialysis, dieticians, and geneticists for genetic counseling are needed in most cases. Emphasis should be placed on enhancing patient-centered care and safety, and all efforts should be targeted towards enhancing patient outcomes.</p>
      </sec>
      <sec id="article-23094.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23094&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23094">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/hyperammonemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23094">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23094/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23094">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23094.s15">
        <fig id="article-23094.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Laboratory diagnosis of diseases causing hyperammonemia Created and Contributed by Rimsha Ali, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23094.s16">
        <title>References</title>
        <ref id="article-23094.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Upadhyay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Busl</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Hyperammonemia: What Urea-lly Need to Know: Case Report of Severe Noncirrhotic Hyperammonemic Encephalopathy and Review of the Literature.</article-title>
            <source>Case Rep Med</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>8512721</fpage>
            <pub-id pub-id-type="pmid">27738433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olde Damink</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dejong</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Interorgan ammonia trafficking in liver disease.</article-title>
            <source>Metab Brain Dis</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-81</page-range>
            <pub-id pub-id-type="pmid">19067143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Barmore</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Azad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Urea Cycle</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30020695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arranz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Riudor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marco-Mar&#x000ed;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-26</page-range>
            <pub-id pub-id-type="pmid">17334707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yachha</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Saraswat</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Encephalopathy assessment in children with extra-hepatic portal vein obstruction with MR, psychometry and critical flicker frequency.</article-title>
            <source>J Hepatol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-54</page-range>
            <pub-id pub-id-type="pmid">20137823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Jonghe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Janier</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abderrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hillion</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lacherade</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Outin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract infection and coma.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Sep</month>
            <day>28</day>
            <volume>360</volume>
            <issue>9338</issue>
            <fpage>996</fpage>
            <pub-id pub-id-type="pmid">12383670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Felig</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Brusilow</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency.</article-title>
            <source>Gastroenterology</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>109</volume>
            <issue>1</issue>
            <fpage>282</fpage>
            <page-range>282-4</page-range>
            <pub-id pub-id-type="pmid">7797025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zafar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spalding</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jonnalagadda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>340</fpage>
            <page-range>340-3</page-range>
            <pub-id pub-id-type="pmid">11276280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vieux</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Valproate-induced hyperammonemic encephalopathy: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2020</year>
            <month>Jan</month>
            <day>25</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">31980035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.</article-title>
            <source>J Child Neurol</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-60</page-range>
            <pub-id pub-id-type="pmid">15794187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Summar</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dobbelaere</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brusilow</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes.</article-title>
            <source>Acta Paediatr</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>97</volume>
            <issue>10</issue>
            <fpage>1420</fpage>
            <page-range>1420-5</page-range>
            <pub-id pub-id-type="pmid">18647279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llansola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Monfort</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montoliu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kosenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cauli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Piedrafita</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>El Mlili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Felipo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>NMDA receptors in hyperammonemia and hepatic encephalopathy.</article-title>
            <source>Metab Brain Dis</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>3-4</issue>
            <fpage>321</fpage>
            <page-range>321-35</page-range>
            <pub-id pub-id-type="pmid">17701332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sepehrinezhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zarifkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Namvar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shahbazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Astrocyte swelling in hepatic encephalopathy: molecular perspective of cytotoxic edema.</article-title>
            <source>Metab Brain Dis</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>559</fpage>
            <page-range>559-578</page-range>
            <pub-id pub-id-type="pmid">32146658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaquero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Blei</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of hepatic encephalopathy in acute liver failure.</article-title>
            <source>Semin Liver Dis</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-69</page-range>
            <pub-id pub-id-type="pmid">14523679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clay</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hainline</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Hyperammonemia in the ICU.</article-title>
            <source>Chest</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>1368</fpage>
            <page-range>1368-78</page-range>
            <pub-id pub-id-type="pmid">17934124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosario</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Diffusion-weighted imaging in acute hyperammonemic encephalopathy.</article-title>
            <source>Neurohospitalist</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>125</fpage>
            <page-range>125-30</page-range>
            <pub-id pub-id-type="pmid">24167645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>U-King-Im</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soobrah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kucharczyk</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Acute hyperammonemic encephalopathy in adults: imaging findings.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>413</fpage>
            <page-range>413-8</page-range>
            <pub-id pub-id-type="pmid">21087942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takanashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barkovich</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Weisiger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zlatunich</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Mudge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tuchman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Packman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2003</year>
            <season>Jun-Jul</season>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1184</fpage>
            <page-range>1184-7</page-range>
            <pub-id pub-id-type="pmid">12812952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ames</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Luckritz</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A retrospective review of outcomes in the treatment of hyperammonemia with renal replacement therapy due to inborn errors of metabolism.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>1761</fpage>
            <page-range>1761-1769</page-range>
            <pub-id pub-id-type="pmid">32232638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Camacho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rioseco-Camacho</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2012</year>
            <month>5</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">22649802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arbeiter</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kranz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wingen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bonzel</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dohna-Schwake</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hanssler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Neudorf</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hoyer</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>B&#x000fc;scher</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>1257</fpage>
            <page-range>1257-65</page-range>
            <pub-id pub-id-type="pmid">19934086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Als-Nielsen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nonabsorbable disaccharides for hepatic encephalopathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2004</year>
            <issue>2</issue>
            <fpage>CD003044</fpage>
            <pub-id pub-id-type="pmid">15106187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bass</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poordad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leevy</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Sigal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Beavers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Teperman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hillebrand</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bortey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin treatment in hepatic encephalopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Mar</month>
            <day>25</day>
            <volume>362</volume>
            <issue>12</issue>
            <fpage>1071</fpage>
            <page-range>1071-81</page-range>
            <pub-id pub-id-type="pmid">20335583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saraswat</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Saksena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rathore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of mannitol effect in patients with acute hepatic failure and acute-on-chronic liver failure using conventional MRI, diffusion tensor imaging and in-vivo proton MR spectroscopy.</article-title>
            <source>World J Gastroenterol</source>
            <year>2008</year>
            <month>Jul</month>
            <day>14</day>
            <volume>14</volume>
            <issue>26</issue>
            <fpage>4168</fpage>
            <page-range>4168-78</page-range>
            <pub-id pub-id-type="pmid">18636662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liotta</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lizza</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Romanova</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Guth</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ganger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ladner</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Naidech</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>23.4% Saline Decreases Brain Tissue Volume in Severe Hepatic Encephalopathy as Assessed by a Quantitative CT Marker.</article-title>
            <source>Crit Care Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>171</fpage>
            <page-range>171-9</page-range>
            <pub-id pub-id-type="pmid">26308431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohsenin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Assessment and management of cerebral edema and intracranial hypertension in acute liver failure.</article-title>
            <source>J Crit Care</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>783</fpage>
            <page-range>783-91</page-range>
            <pub-id pub-id-type="pmid">23683564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
            </person-group>
            <article-title>L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-14</page-range>
            <pub-id pub-id-type="pmid">18823442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bustamante</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rimola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ventura</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Navasa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cirera</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reggiardo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rod&#x000e9;s</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prognostic significance of hepatic encephalopathy in patients with cirrhosis.</article-title>
            <source>J Hepatol</source>
            <year>1999</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>890</fpage>
            <page-range>890-5</page-range>
            <pub-id pub-id-type="pmid">10365817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23094.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardenas</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Bodensteiner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Osmotic demyelination syndrome as a consequence of treating hyperammonemia in a patient with ornithine transcarbamylase deficiency.</article-title>
            <source>J Child Neurol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>884</fpage>
            <page-range>884-6</page-range>
            <pub-id pub-id-type="pmid">19225137</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
